Stocks
Jasper Therapeutics, Inc.JSPR
NASDAQHealthcareBiotechnology$0.51
Price as of · delayed, not real-time
A clinical-stage biotechnology company developing therapies for mast cell-driven diseases, including chronic urticaria and other inflammatory conditions. Its lead candidate, JSP191, is a monoclonal antibody targeting the c-Kit receptor, with early-stage trials underway. Investors track JSPR for its potential in addressing unmet needs in mast cell-mediated disorders and its pipeline progress.
52W Range: $0.32-$2.52
Congressional Interest in Jasper Therapeutics, Inc. (JSPR)
No congressional trades have been disclosed for Jasper Therapeutics, Inc. (JSPR) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading JSPR?
No congressional trades found for this stock.